Espervita

2 known investors

Espervita Therapeutics is a drug discovery company developing metabolic reprogramming therapies, with a lead compound (EVT0185) that inhibits acetyl-CoA metabolic enzymes to treat conditions such as MASH, chronic kidney disease, and liver and kidney fibrosis. It focuses on first-in-class small-molecule therapies for metabolic-dysfunction diseases.

Biotech